



12 February 2026

APPOINTMENT OF CHIEF EXECUTIVE OFFICER

Patrys Limited (ASX: **PAB**) (**Patrys**, the **Company**), a therapeutic antibody development company, is pleased to announce the appointment of Dr Samantha South as its Chief Executive Officer (**CEO**), effective 16 February 2026.

Dr South is an experienced biotechnology executive with a strong track record in advancing preclinical assets to clinical readiness, building robust development strategies and guiding life sciences companies through critical value-creation phases in both listed and private environments.

Dr South is a Founding Director of Argenica Therapeutics. She has held senior commercialisation roles at leading Australian research institutions including Queensland University of Technology (QUT) and the University of Western Australia (UWA), establishing multiple licence, options and assignments with industry partners, including large pharmaceutical companies such as Sanofi and Merck. She has been a Director of multiple UWA spin-out biotechnology companies, including MiReven Pty Ltd, Eridan Technologies Pty Ltd, OxiDx Pty Ltd, OncoRes Medical Pty Ltd and Rage Biotech Pty Ltd.

Dr South has provided strategic advice for the development of therapeutics and diagnostics as part of the Innovation Growth Program (Ausbiotech) and as a consultant for a diverse portfolio of both listed and private biotech companies. Most recently, Dr South has served as a Non-Executive Director of Reliis Pty Ltd, prior to its acquisition by Patrys, and is the Chair of the Life Sciences WA Board.

Earlier in her career, Dr South worked in preclinical and regulatory roles at contract research organisations TetraQ and GZP, where she gained extensive hands-on experience supporting translational development programs and regulatory submissions.

Dr South holds a PhD, an MBA and is a Graduate of the Australian Institute of Company Directors (GAICD). Dr South has a background in central nervous system (CNS) medical research which includes working at Weill Medical College at Cornell University (NY), The University of Queensland (UQ) and The Garvan Institute (UNSW).

The Board believes Dr South's depth of experience across translational science, regulatory strategy, capital-efficient drug development and commercialisation is well aligned with Patrys' evolution into a dual-platform, catalyst-driven clinical-stage company, following the recent expansion of its pipeline and focus on accelerating value creation across its portfolio.

Patrys Chair, Peter Christie, said:

"The Board welcomes the appointment of Dr Samantha South as CEO of Patrys. Samantha brings an exceptional combination of scientific depth, regulatory and development expertise, and commercial acumen. Her experience in progressing assets from preclinical development towards the clinic, and her



understanding of capital-efficient biotech execution, make her ideally suited to lead Patrys through its next phase of growth and clinical advancement."

With the recent expansion of our pipeline, the Board was focused on appointing a CEO who can execute with discipline and pace across multiple development pathways. We look forward to working with Dr South as the Company advances its programs."

Dr Samantha South, said:

"I am honoured to be appointed CEO of Patrys at this pivotal juncture in the Company's evolution. Patrys has built a scientifically differentiated platform with meaningful therapeutic potential, and our expanded pipeline provides multiple pathways to create substantial value through near-term clinical and regulatory catalysts.

In partnership with the Board, I am committed to delivering sustained shareholder value through methodical clinical progress, efficient capital deployment and strategic portfolio development."

-Ends-

This announcement is authorised for release by the Board of Directors of Patrys Limited.

For further information, please contact:

General enquiries

Anton Uvarov, PhD
Non-Executive Director
P: + 61 450 662 770
info@patrys.com

Registered Office Address

168 Stirling Highway
Nedlands WA, 6009

About Patrys Limited

Patrys (ASX:PAB) is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. More information can be found at www.patrys.com.

Forward Looking Statements

This announcement may contain certain "forward-looking statements". Forward looking statements can generally be identified by the use of forward-looking words such as, "expect", "should", "could", "may", "predict", "plan", "will", "believe", "forecast", "estimate", "target" and other similar expressions. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.